Quick Answer
In the largest clinical trial of tirzepatide for weight loss (SURMOUNT-1), participants without type 2 diabetes lost an average of approximately 21% of their body weight over 72 weeks on the 15 mg dose. For a person starting at 225 pounds, that would mean losing roughly 47 pounds on average. However, individual results varied considerably — some people lost more and some lost less. Factors including starting weight, dose level, treatment duration, dietary changes, physical activity, and individual biology all affect how much weight a person loses. These results reflect branded FDA-approved tirzepatide (Zepbound) in a controlled clinical trial. Compounded tirzepatide has not been studied in the same way.
Average Weight Loss Shown in Clinical Trials
The SURMOUNT-1 trial is the largest and most frequently cited study of tirzepatide for chronic weight management. It enrolled 2,539 adults with obesity or overweight with at least one weight-related condition, excluding those with type 2 diabetes. Participants received weekly tirzepatide injections at one of three dose levels (5 mg, 10 mg, or 15 mg) or placebo, combined with lifestyle intervention.
SURMOUNT-1 Mean Weight Loss at 72 Weeks
Placebo
2.4%
of body weight
5 mg
15.0%
of body weight
10 mg
19.5%
of body weight
15 mg
20.9%
of body weight
Source: Jastreboff AM, et al. NEJM. 2022. PubMed. Results reflect FDA-approved branded tirzepatide (Zepbound) in a clinical trial. Individual results vary.
Results at 3, 6, 12, and 18 Months
Weight loss with tirzepatide tends to be gradual and progressive, with the largest reductions occurring once the maintenance dose is reached — typically after several months of dose escalation.
| Time on Treatment | Approximate Dose Reached | Estimated Mean Weight Loss |
|---|---|---|
| 3 months (~12 weeks) | 7.5–10 mg | ~8% of body weight |
| 6 months (~24 weeks) | 10–15 mg | ~14% of body weight |
| 12 months (~48 weeks) | 15 mg (maintenance) | ~19% of body weight |
| 18 months (~72 weeks) | 15 mg (maintenance) | ~21% of body weight |
Estimates are approximate and based on published SURMOUNT-1 data. Individual dose levels and rate of loss differ. The licensed provider adjusts the titration schedule based on response and tolerability. Compounded tirzepatide has not been studied in published clinical trials of this scale.
Why Results Differ Among Patients
Weight-loss results with tirzepatide are not uniform. The SURMOUNT-1 trial showed that while the mean weight loss was about 21% on the 15 mg dose, individual results ranged widely. Understanding why can help set realistic expectations.
Starting body weight
People with higher starting weights tend to lose more total pounds, though the percentage of body weight lost may be similar regardless of starting weight.
Dose achieved
In SURMOUNT-1, higher doses produced greater weight loss on average. Not all patients reach or tolerate the 15 mg maximum dose, and the licensed provider determines the appropriate maintenance dose.
Duration of treatment
Weight loss typically continues as long as treatment is maintained and the therapeutic dose is tolerated. Stopping treatment early usually means less total weight loss.
Diet and physical activity
SURMOUNT-1 included lifestyle intervention for all participants. The medication supports dietary changes — it does not replace them. Individual dietary adherence and activity level influence results.
Individual biology
Genetic factors, hormone levels, gut microbiome composition, and metabolic rate all vary between individuals and affect medication response in ways that are not yet fully understood.
Side-effect tolerance
People who experience significant gastrointestinal side effects may titrate more slowly or stop at a lower dose, potentially affecting total weight loss.
Effect of Dose and Treatment Duration
Higher tirzepatide doses were associated with greater mean weight loss in clinical trials, but the relationship is not perfectly linear.
In SURMOUNT-1, the 15 mg dose produced about 21% weight loss, while 10 mg produced about 19.5%, and 5 mg about 15% — each statistically significant relative to placebo. However, the additional benefit between 10 mg and 15 mg was smaller than the jump between 5 mg and 10 mg.
Treatment duration also matters. Weight loss generally continued throughout the 72-week trial period, though the rate of loss slowed over time — a pattern typical of most weight-loss interventions. People who maintain treatment longer generally maintain more weight loss. A separate study (SURMOUNT-4) showed that people who continued tirzepatide after an initial 36-week period lost additional weight, while those switched to placebo regained weight.
Source: Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity — SURMOUNT-4. JAMA. 2024. PubMed
Example Calculations by Starting Weight
The following table applies SURMOUNT-1 mean weight-loss percentages to different starting weights. These are mathematical illustrations only. They do not predict or guarantee individual results.
| Starting Weight | 3 months (~12 weeks) | 6 months (~24 weeks) | 12 months (~48 weeks) | 18 months (~72 weeks) |
|---|---|---|---|---|
| 180 lbs | ~14 lbs → ~166 lbs | ~25 lbs → ~155 lbs | ~34 lbs → ~146 lbs | ~38 lbs → ~142 lbs |
| 200 lbs | ~16 lbs → ~184 lbs | ~28 lbs → ~172 lbs | ~38 lbs → ~162 lbs | ~42 lbs → ~158 lbs |
| 225 lbs | ~18 lbs → ~207 lbs | ~32 lbs → ~193 lbs | ~43 lbs → ~182 lbs | ~47 lbs → ~178 lbs |
| 250 lbs | ~20 lbs → ~230 lbs | ~35 lbs → ~215 lbs | ~48 lbs → ~202 lbs | ~53 lbs → ~197 lbs |
| 300 lbs | ~24 lbs → ~276 lbs | ~42 lbs → ~258 lbs | ~57 lbs → ~243 lbs | ~63 lbs → ~237 lbs |
All numbers above are mathematical illustrations applying SURMOUNT-1 mean percentages. Individual results vary substantially. These are not predictions or guarantees. Compounded tirzepatide has not been studied in published clinical trials of this scale.
Example Calculator: Illustrate SURMOUNT-1 Averages
Enter a starting weight to see how published clinical trial averages would translate. This is a mathematical illustration only — it does not predict or guarantee individual results.
When Weight Loss May Begin
Many people begin to notice weight loss within the first 4 weeks, even at the starting dose. In SURMOUNT-1, participants on tirzepatide showed measurable weight reduction as early as week 4 — the first assessment point after the 2.5 mg starting dose.
However, the rate of loss typically accelerates as the dose increases. The starting dose of 2.5 mg is not considered a therapeutic dose — it's designed to help your body adjust. More substantial weight loss usually occurs once doses reach 5 mg and above, which is typically after the first month.
If you haven't noticed weight loss after 4–6 weeks, that is not necessarily concerning. Your provider may adjust the dose or titration pace. Results also depend on dietary changes, physical activity, and individual biology.
What a Plateau May Mean
A weight-loss plateau — a period where weight stays stable despite continued treatment — is common and does not necessarily mean the medication has stopped working. Plateaus can occur at any point during treatment and may last weeks or longer.
Possible reasons for a plateau include: the body adjusting to a new lower metabolic set point (a natural physiological response to weight loss), dietary habits drifting over time, reduced physical activity, or stress and sleep disruption affecting hormone regulation.
If you experience a prolonged plateau, discuss it with your licensed provider. They may evaluate whether a dose adjustment, dietary changes, or other modifications are appropriate for your situation.
How Nutrition, Activity, Side Effects, and Adherence Affect Results
Tirzepatide is a powerful tool for weight loss, but it works alongside — not instead of — lifestyle factors.
Nutrition
Tirzepatide reduces appetite, making it easier to eat less without constant hunger. However, the quality of what you eat still matters. A diet rich in protein, fiber, vegetables, and whole foods supports lean muscle retention and overall health during weight loss. Clinical trials included structured dietary counseling alongside medication.
Physical activity
SURMOUNT-1 participants received lifestyle counseling that included a recommendation for at least 150 minutes of physical activity per week. Exercise helps preserve muscle during weight loss, supports cardiovascular health, and may improve mood and sleep — all of which can indirectly support sustained weight management.
Side-effect management
Gastrointestinal side effects like nausea can temporarily reduce food intake, which may accelerate early weight loss — but persistent side effects can also make adherence difficult and lead to dose reductions or treatment discontinuation. Working with your provider on a comfortable titration pace can help.
Adherence
Missing doses or stopping treatment interrupts weight loss. Tirzepatide is a once-weekly injection. Consistent weekly dosing supports steady results. In SURMOUNT-4, people who stopped tirzepatide regained weight, while those who continued treatment maintained or extended their loss.
What Happens After Stopping Treatment
In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo after 36 weeks regained a significant proportion of the weight they had lost, while those who continued treatment maintained or extended their loss.
Specifically, after 52 additional weeks (88 weeks total), the group that stayed on tirzepatide lost an additional 5.5% on average, while the group switched to placebo regained 14% of their initial loss. This suggests that tirzepatide treats obesity as a chronic condition — ongoing treatment may be necessary to maintain results for many people.
If you are considering stopping treatment, speak with your licensed provider. They can help you plan for the transition, discuss maintenance strategies, and determine whether an alternative approach is appropriate.
Source: Aronne LJ, et al. SURMOUNT-4. JAMA. 2024. PubMed
FDA-Approved Versus Compounded Formulations
All weight-loss results described above come from clinical trials of FDA-approved branded tirzepatide (Zepbound). Compounded tirzepatide has not been studied in published clinical trials of this scale.
Compounded tirzepatide is prepared by state-licensed compounding pharmacies based on a prescription from a licensed provider. This does not mean compounded tirzepatide is ineffective — it means that the clinical trial evidence base for compounded formulations is different from the evidence base for branded Zepbound.
If you are prescribed compounded tirzepatide, the relevant clinical data (SURMOUNT-1, SURMOUNT-4, SURMOUNT-5) provides useful context for understanding tirzepatide's effects, but it does not guarantee that compounded preparations will produce identical results. Prescribing decisions are made by licensed providers. Individual results vary.
When to Contact a Licensed Provider
Regular communication with your licensed provider is a normal part of GLP-1 treatment. Contact your provider promptly if you experience any of the following:
- Severe or persistent nausea, vomiting, or diarrhea that does not improve with dose adjustments
- Signs of gallbladder problems, including severe upper abdominal pain, fever, or yellowing of the skin or eyes
- Unusually rapid weight loss (significantly exceeding what you and your provider discussed)
- Symptoms of pancreatitis, including severe abdominal pain that may radiate to the back, with or without vomiting
- Signs of an allergic reaction, including rash, swelling, or difficulty breathing
- New or worsening depression, mood changes, or thoughts of self-harm
- Pregnancy or plans to become pregnant — tirzepatide should be discontinued before a planned pregnancy
This list is not exhaustive. Always follow your provider's guidance and seek emergency care for severe or concerning symptoms.
Key Takeaways
- In SURMOUNT-1, participants on tirzepatide 15 mg lost an average of approximately 21% of body weight over 72 weeks.
- Weight loss is gradual — measurable within the first month, with the largest reductions occurring after reaching the maintenance dose.
- Results vary widely. Factors like starting weight, dose, treatment duration, diet, activity, and individual biology all influence outcomes.
- A weight-loss plateau is common and does not mean the medication has stopped working.
- In SURMOUNT-4, people who stopped tirzepatide regained weight while those who continued maintained or extended their loss.
- All clinical trial weight-loss results come from studies of FDA-approved branded tirzepatide.
- No result is guaranteed. Prescribing decisions are made by licensed providers based on individual patient assessment.
See Whether GLP-1 Treatment May Be Appropriate
Complete a private online assessment. A licensed provider will review your health information and determine whether treatment is appropriate.
Check My EligibilityComplete a private health assessment. A licensed provider will determine whether treatment is appropriate for you. Individual results vary. Compounded medications are not FDA-approved.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216. PubMed
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. accessdata.fda.gov
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity — SURMOUNT-4. JAMA. 2024;331(1):38-48. PubMed
- National Institutes of Health. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
- Trico D, et al. Tirzepatide vs Semaglutide for Weight Loss — SURMOUNT-5. JAMA Internal Medicine. 2025. PubMed
- U.S. Food and Drug Administration. Compounding and FDA: Questions and Answers. fda.gov
Glossary
- GIP (glucose-dependent insulinotropic polypeptide)
- A hormone that stimulates insulin secretion after eating and may influence fat metabolism. Tirzepatide activates both GIP and GLP-1 receptors.
- GLP-1 (glucagon-like peptide-1)
- A hormone that signals the brain to reduce appetite, slows stomach emptying, and stimulates insulin release when blood sugar is high.
- Placebo
- An inactive substance used as a control in clinical trials. In SURMOUNT-1, the placebo group lost about 2.4% of body weight on average, likely due to the lifestyle intervention component.
- Titration
- The gradual process of increasing a medication dose over time to reach a therapeutic level while monitoring for side effects.
- Mean weight loss
- The arithmetic average weight loss across all participants in a study group. Individual results may be higher or lower than the mean.